Insomnia News

Researchers have found that 43 percent of patients undergoing chemotherapy for cancer in a clinical trial met the clinical criteria for insomnia syndrome and an additional 37 percent had insomnia symptoms, suggesting that the majority of patients experience sleep difficulties.

Main Category: Cancer / Oncology Also Included In: Sleep / Sleep Disorders / Insomnia Article Date: 24 Nov 2009 Researchers have found that 43 percent of patients undergoing chemotherapy for cancer in a clinical trial met the clinical criteria for insomnia syndrome and an additional 37 percent had insomnia symptoms, suggesting that the majority of ...

Main Category: Sleep / Sleep Disorders / Insomnia Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials Transcept Pharmaceuticals, Inc.

Three quarters of cancer patients and survivors treated with chemotherapy suffer insomnia or sleep disorders that often become chronic conditions, hindering patients' ability to fully recover, according to scientists at the University of Rochester Medical Center.

Whether it's in the bottom of a bottle of pills, a glass of wine, or a cup of herbal tea, many of us are searching for a good night's rest.

When one is facing the desperation of another sleepless night, it may be natural to wonder if treating insomnia is possible with the use of aromatherapy .

Forget sleeping pills and sedative hypnotics, like Nytol and Ambien, a UK-based company has produced a natural solution to insomnia, the LightSleeper.

Amityville-based pharmaceutical company Hi-Tech Pharmacal on Monday said it has signed a deal to market Zolpimist, a drug used to treat insomnia, in the United States and Canada.

Main Category: IT / Internet / E-mail Also Included In: Primary Care / General Practice Article Date: 11 Nov 2009 Simple computerized alerts can help curb the impulse to prescribe unnecessarily expensive, heavily marketed drugs, according to a study in the August issue of Journal of General Internal Medicine .

Simple computerized alerts can help curb the impulse to prescribe unnecessarily expensive, heavily marketed drugs, according to a study in the August issue of Journal of General Internal Medicine.

The weekly poll THIS WEEK'S TOPIC: Do you trust the 73-year-old Bay Bridge? No, I speed up at the S-turn X 15% Yes, there's an army of safety inspectors now X 10% No, another reason to stay in the East Bay X 20% Yes, but looking... Trade reform - save jobs, save the planet David Sirota, 2009 Creators.com Trade and globalization - when not ...

Takeda Pharmaceutical Co., Asia's biggest drugmaker, sued Teva Pharmaceutical Industries Ltd., alleging infringement of a U.S. patent for the insomnia treatment Rozerem.

Trade and globalization -- when not referencing blockbuster sports transactions or raucous street protests, debates over these abstract terms can give Ambien and Jack Daniels a run for their money as a cure for insomnia.

NovaDel Pharma Inc. , today announced that it received a Notice of Allowance from the United States Patent and Trademark Office for claims under U.S. Patent Application No.

Transcept Pharmaceuticals received disappointing news from the FDA regarding the company's New Drug Application for its insomnia treatment.

Fed up with tossing and turning instead of sleeping? Exhausted from waking at 3 a.m. and not being able to get back to sleep? Help is available in a form that might surprise you: talk therapy.

What should have been a dream approval for Transcept Pharmaceuticals has turned into a nightmare for the Californian company, which now faces a significant delay to the launch of its middle of the night waking insomnia drug Intermezzo .

Do you toss and turn at night because of fibromyalgia pain or discomfort? "People with fibromyalgia tend to have very disturbed sleep," says Doris Cope, MD, director of Pain Management at the University of Pittsburgh School of Medicine.

Transcept Pharmaceuticals said Thursday the Food and Drug Administration wants additional safety data on the developing insomnia drug Intermezzo to consider it for regulatory approval.

Transcept Pharmaceuticals announced today that the U.S. Food and Drug Administration issued a Complete Response Letter regarding the New Drug Application for Intermezzo .